Onchilles Pharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Onchilles Pharma, Inc. - overview
Established
2017
Location
San Diego, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2017, Onchilles Pharma, Inc. operates as a biotechnology company that develops first-in-class drug candidates. The company was co-founded by Court R. Turner and Lev Becker and is backed by Series A investors Lyzz Capital and UChicago Startup Investment Program in June 2021.
The company's line of product includes ELANE (Elastase, Neutrophil Expressed) is a new treatment paradigm that helps to kills cancer cells regardless of genetic mutation or anatomical origin. Onchilles Pharma plans to advance the first drug candidate through preclinical proof-of-concept and interrogate the novel pathway for further pipeline development.
Current Investors
Lincoln Park Capital, Lyzz Capital, UChicago Startup Investment Program
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.onchillespharma.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.